|1.||Shvidel, Lev: 3 articles (07/2014 - 09/2010)|
|2.||Berrebi, Alain: 3 articles (07/2014 - 09/2010)|
|3.||Ferrone, Soldano: 3 articles (06/2008 - 02/2004)|
|4.||Polliack, Aaron: 2 articles (07/2014 - 10/2012)|
|5.||Rahimi-Levene, Naomi: 2 articles (07/2014 - 10/2012)|
|6.||Braester, Andrei: 2 articles (07/2014 - 10/2012)|
|7.||Ruchlemer, Rosa: 2 articles (07/2014 - 10/2012)|
|8.||Klepfish, Abraham: 2 articles (07/2014 - 10/2012)|
|9.||Israeli CLL Study Group: 2 articles (07/2014 - 10/2012)|
|10.||Bairey, Osnat: 2 articles (07/2014 - 10/2012)|
08/01/2003 - "Two successive controls were made in a subset of 30 patients, categorized in three groups (improved, stable, worsened) according to the behavior of tumor burden markers (bone marrow plasmacytosis, monoclonal component, and beta(2)-microglobulin). "
05/24/1994 - "Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors."
08/01/1986 - "[Fundamental and clinical studies on the measurement of beta 2-microglobulin as a tumor marker using the Dainabot beta 2-micro-radioimmunoassay kit]."
06/01/2004 - "No statistical significance was obtained when HLA and beta 2 microglobulin immunoreactivity was compared against largest tumor diameter (LTD), tumor infiltrating lymphocytes (TIL), mitosis and nuclear grade. "
04/01/2004 - "beta 2-microglobulin aided the MHC tumor inhibition but did not inhibit tumor without the MHC. "
12/01/1985 - "Serum beta 2-microglobulin: a real improvement in the management of multiple myeloma?"
10/01/1985 - "Serum beta 2-microglobulin at remission and relapse in patients with multiple myeloma."
11/21/1992 - "The aim of the present study was to compare the prognostic influence of beta 2-microglobulin (B2M) corrected according to renal function versus the uncorrected form and relate these values with other characteristics of the disease in a series of patients with multiple myeloma (MM). "
03/01/1991 - "From a retrospective multivariate study on 107 multiple myeloma (MM) patients, serum beta 2-microglobulin (beta 2M) proved to be the best prognostic discriminator, better than each of the currently used staging systems (Durie and Salmon's [DS], Merlini, Waldenström and Jayakar's [MWJ] and the British Medical Research Council's [BMRC]). "
08/01/1990 - "The prognostic value of serum beta 2 microglobulin (s beta 2m) measured at entry, at plateau and at 3-monthly follow-up times has been assessed for patients in the Medical Research Council's 4th and 5th Myelomatosis Trials. "
09/01/2008 - "There was evidence of other signs of renal tubular impairment (urinary beta-2-microglobulin 213 mg/L, glomerulotubular proteinuria 1.01g/24h). "
10/01/2005 - "There was no statistically significant difference among the three groups in terms of the results of FE(Na) (%), FE(Mg) (%), FE(UA) (%), TPR (%), calciuria (mg/kg per 24 h), NAG, urine Zn, proteinuria, glucosuria or urine beta- 2 microglobulin levels (P > 0.05). "
05/01/2004 - "To assess proteinuria and urinary beta 2-microglobulin as prognostic factors in AP. "
07/01/1995 - "Urinary alpha 1- and beta 2-microglobulin in light chain proteinuria."
04/01/1992 - "The other 4 affected family members also had low-molecular-weight proteinuria, detected by screening for beta 2-microglobulin. "
|4.||Diabetic Nephropathies (Diabetic Nephropathy)
08/01/1992 - "However, no relationships were found between the increased urinary albumin excretion (incipient and/or overt diabetic nephropathy) at follow-up to either the initial glomerular filtration rate (134 vs 137 ml min-1 1.73 m-2; p greater than 0.05) or to renal tubular function assessed from urinary excretion rate of beta 2-microglobulin (0.059 vs 0.069 microgram min-1; p greater than 0.05) and the renal threshold concentration of phosphate per litre of glomerular filtrate (1.29 vs 1.22 mmol l-1; p greater than 0.05)."
12/01/1983 - "[Early detection of diabetic nephropathy: serum beta 2-microglobulin]."
04/26/1992 - "Diabetic nephropathy was recorded with the measurements of serum creatinine, serum beta 2-microglobulin, and urine albumin excretion. "
01/01/1985 - "Neither serum creatinine nor serum beta 2-microglobulin can be used as methods for screening of early impairment of renal function (GFR less than 80 ml/min/1.73 m2 in diabetic nephropathy. "
09/30/1983 - "Serum creatinine was a significantly better predictor of GFR than serum beta 2-microglobulin in patients with diabetic nephropathy, whereas both methods were equally useful predictors of GFR in non-diabetic renal disease. "
01/01/1990 - "The data obtained indicate that the beta 2-microglobulin test is of great help for the control of remission completeness in acute leukemias and for early diagnosis of relapses."
06/01/1989 - "Patients with acute lymphatic leukemia had elevated values of beta 2 microglobulin while the disease was active (3.37 mg/l), decreasing to normal levels after remission (1.79 mg/l). "
03/04/1994 - "Regulation of the expression of major histocompatibility complex (MHC) class I heavy chains not associated with beta 2-microglobulin (beta 2m) on freshly isolated and in vitro cultured human B and T leukemia cells was analyzed. "
01/01/1990 - "Measurements of the serum and urinary beta 2-microglobulin (beta 2-Mg) concentrations in 138 adult patients with various forms of acute leukemia, which were carried out in various periods of the disease, have revealed that serum beta 2-Mg levels were two times higher in the patients with leukemic involvement of the kidneys (5.54 +/- 3.50 mg/l) than in those without renal involvement (2.77 +/- 1.07 mg/l). "
01/01/1990 - "[Beta 2-microglobulin in the diagnosis of specific involvement of the kidneys in acute leukemias]."
|3.||Proteins (Proteins, Gene)
|6.||Amyloid (Amyloid Fibrils)
|10.||Interleukin-6 (Interleukin 6)
|2.||Drug Therapy (Chemotherapy)
|5.||Combination Drug Therapy (Combination Chemotherapy)